Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00055185 | Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients | PHASE2 | COMPLETED | 24 | — | — | Apr 1, 2003 | Jun 1, 2005 | Oct 3, 2008 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| CD4-IgG2 (PRO 542) | DRUG | - |
Inclusion Criteria: * Confirmed diagnosis of HIV * Patients must be on a stable dose of acceptable anti-HIV therapy or receiving no anti-HIV therapy for at least four (4) weeks prior to the start of this study * HIV-1 determination by RNA-PCR greater than or equal to 100,000 copies/ml * CD4 count \...